| scholarly article | Q13442814 |
| P356 | DOI | 10.12968/BJON.2013.22.6.308 |
| P698 | PubMed publication ID | 23901448 |
| P2093 | author name string | Deborah Palmer | |
| Yasser El Mledany | |||
| P2860 | cites work | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 |
| Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha | Q28394197 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad | Q33614786 | ||
| Total cholesterol and LDL levels decrease before rheumatoid arthritis | Q33931317 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases | Q34129198 | ||
| Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial | Q34651182 | ||
| American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
| Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response | Q36930634 | ||
| Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review | Q37158791 | ||
| Prospective new biological therapies for rheumatoid arthritis | Q37425627 | ||
| Demyelination as a complication of new immunomodulatory treatments | Q37742372 | ||
| Safety profile of abatacept in rheumatoid arthritis: a review | Q37811541 | ||
| Clinical safety of tocilizumab in rheumatoid arthritis | Q37814417 | ||
| Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis | Q37828398 | ||
| Current understanding of rheumatoid arthritis therapy | Q37987351 | ||
| Developing an effective treatment algorithm for rheumatoid arthritis | Q38020465 | ||
| Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies | Q41918491 | ||
| COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention | Q43882911 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial | Q44985061 | ||
| Future of RA: building on what we know and tailoring treatment. | Q51583230 | ||
| Rheumatoid arthritis | Q56656479 | ||
| Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry | Q56838445 | ||
| P433 | issue | 6 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 308, 310, 312-8 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | British Journal of Nursing | Q15754463 |
| P1476 | title | Treat-to-target: a tailored treatment approach to rheumatoid arthritis | |
| P478 | volume | 22 |
Search more.